CLINICAL TRIALS

Fullerton neurology and Headache Center regularly perform research in many neurological diseases.Why should I participate in a clinical trial?

Help researchers uncover better ways to prevent, diagnose, treat and understand various neurological diseases.

Clinical trials provide access to treatments which are otherwise unavailable.

We are currently recruiting for the following trials:

CHRONIC MIGRANE IN ADULTS
(C-BEOND)

ClinicalTrials.gov NCT#06047444
Sponsor: Ipsen

A Phase III, Randomized, Double-blind, Placebo-controlled, study with an extension phase to evaluate the efficacy and safety of Dysport for the prevention of Chronic Migraine (15 or more headache days a month) in adults.

The study will consist of 3 periods:

  1. Screening period of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit.
  2. A first treatment phase of 24 weeks. On day 1 and at week 12 of the fisrt treatment phase, participants will receive injections into various muscles across the head, neck, face and shoulders.
  3. A second treatment phase of 24 weeks (extension phase). At week 24 and at week 36, all participants will get Dysport® (dose “A” or dose “B”)

Episodic Migraine in Adults
(E-BEOND)

ClinicalTrials.gov NCT#06047457
Sponsor: Ipsen

A Phase III, Randomized, Double-blind, Placebo-controlled, study with an extension phase to evaluate the efficacy and safety of Dysport for the prevention of Episodic Migraine (up to 14 headache days a month) in adults.

The study will consist of 3 periods:

  1. Screening period of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit.
  2. A first treatment phase of 24 weeks. On day 1 and at week 12 of the fisrt treatment phase, participants will receive injections into various muscles across the head, neck, face and shoulders.
  3. A second treatment phase of 24 weeks (extension phase). At week 24 and at week 36, all participants will get Dysport® (dose “A” or dose “B”)

Mysathenia Gravis

Sponsor: Novartis

Phase III clinical trial in adult patients with generalized Myasthenia Gravis. The primary objective of this study is to demonstrate the safety and efficacy of an alternative oral complement inhibitor versus placebo in patients with Myasthenia Gravis who are receiving stable, standard-of-care treatment.

After completion of 6 months (26 weeks) of double-blind treatment (1:1 active or placebo), patients will be offered to continue in an Open-Label Extension (OLE) study and will receive medication at no charge for at least 24 months.

Essential Tremor
(KINETIC 2)

ClinicalTrials.gov NCT#05173012
Sponsor: Sage

Phase III clinical trial for patients aged 18-80, Ranomized, Double-blind, Placebo-controlled. Three doses with change of placebo of 1:4.
? Weeks of active treatment followed by an open label extension

BOOK AN APPOINTMENT
For information or to enroll in a trial, please contact Alexandra Vasquez by phone at (714) 738-3845